This move is archived. Current quotes and coverage live on the stock page.
Follow GILD
Gilead Sciences Inc. is experiencing a notable decline in stock value amidst recent FDA approvals and market concerns.
Gilead Sciences Inc. (NASDAQ:GILD) saw its stock price drop by 2.43% in today's trading session, closing at CA$147.33. Despite recent FDA approvals for its new HIV treatment Bixlenvo, investor sentiment appears to be shifting negatively.
Investor takeaway: While Gilead's new product approvals may indicate growth potential, the narrow target market and existing competition raise questions about the stock's immediate viability.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$187.44B
Div. yield
2.19%
Div. / share
$3.22
52W high
$154.51
52W low
$111.27
1W change
+4.01%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 12, 2026
Wall Street analysts forecast GILD stock price to rise 423.8% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.38
+423.8% Upside
Previously C$159.27 on Oct 9, 2026
Current Price
C$30.43
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
20.8%
Annualized
90-Day Vol
27.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$179.84
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$159.66 | C$148.59 – C$171.54 |
| 60 trading days | C$169.45 | C$153.08 – C$187.56 |
| 90 trading days | C$179.84 | C$158.80 – C$203.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
The approval of Bixlenvo adds to Gilead's HIV treatment options, potentially making it easier for a small group of patients who currently manage complex regimens. This could help Gilead capture a larger share of the market.
Bear case
However, Bixlenvo targets only 5% of HIV patients, and with strong competition and pricing pressures, Gilead might find it challenging to achieve significant revenue growth from this product.
Recent Developments
Gilead recently received FDA approval for Bixlenvo, a once-daily pill for adults with suppressed HIV. While this approval could simplify treatment for a small group of patients, it only addresses about 5% of the HIV population currently using complex multi-pill regimens.
Advertisement
Market Response
Despite the positive news surrounding Bixlenvo, Gilead's stock has declined by 2.43% today, reflecting investor concerns about the narrow market potential and the competitive landscape. The existing competition in the HIV treatment market, including Merck's Idvynso, adds to the uncertainty surrounding Gilead's ability to capture significant market share.
Looking Ahead
Investors are urged to consider the implications of Bixlenvo's limited target market and the potential for pricing pressures as Gilead navigates a challenging landscape. The success of this new treatment will largely depend on its adoption rate among eligible patients and how effectively Gilead can differentiate it from existing therapies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
